Brief: Bioinvent Gets IND Approval For Clinical Trial
02/06/2023 07:08
June 2 (Reuters) - BioInvent International AB BINV.ST :
* BIOINVENT OBTAINS IND APPROVAL FOR CLINICAL TRIAL WITH
ANTI-TNFR2 ANTIBODY BI-1910
* DIFFERENTIATED -AGONIST- APPROACH FROM BI-1808,
FIRST-IN-CLASS
ANTIBODY CURRENTLY IN PHASE 1 CLINICAL DEVELOPMENT
Source text for Eikon: ID:nMFN59N6B7
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))